Ipsen SA Reports 11.6% Q1 2025 Sales Growth, Driven by Strong Performance and Key Products
Ipsen SA reported a 11.6% sales growth in Q1 2025, driven by strong performance across all therapeutic areas and contributions from products Iqirvo and Bylvay.
One minute to read